AxioMed Spine completes $3.6 million financing round
AxioMed Spine announced this week that it has completed a new round of financing, raising $3.6 million from current and new investors.
The Garfield Heights company develops products designed to restore spinal function in patients with degenerative spine disease by advancing the standard of care beyond fusion and first generation total disc replacement. Their lumbar and cervical discs have received CE Mark approval for distribution in Europe. The company also is pursuing US regulatory approval for the products.